BioSpace News Archive

GenFleet Therapeutics today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/refractory PTCL (peripheral T-cell lymphomas) patients.

Results from Magenta Medical’s Early Feasibility Study of the Elevate™ System, for the high-risk percutaneous coronary intervention (HR-PCI) indication, will be announced in an oral presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco. Elevate™ is the world’s smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company’s novel, investigational orexin 2 receptor (OX2R).

South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023.

VUZE Medical , a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has submitted a 510(k) filing with the U.S. Food and Drug Administration (FDA) for VUZE 2.0, its second generation VUZE System.

BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming Pharma Partnering Summit in Boston October 19-20, 2023.

BridgeBio Pharma, Inc. announced that the proof-of-concept Phase 2b data evaluating the effects of orally-administered encaleret on mineral homeostasis in patients with ADH1 were published in the New England Journal of Medicine in partnership with the National Institutes of Health (NIH).

ImmPACT Bio USA , Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-514, a potential first-in-class CD19/CD20 CAR-T therapy for the treatment of patients with active refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE).

CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC, announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa region.

Acurex Biosciences Corporation has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J. Fox Foundation.